Kikuchi-Fujimoto disease can present as delayed lymphadenopathy after COVID-19 vaccination

Hum Vaccin Immunother. 2022 Nov 30;18(5):2071080. doi: 10.1080/21645515.2022.2071080. Epub 2022 May 18.

Abstract

Following COVID-19 vaccination, ipsilateral axillary and cervical lymphadenopathy may occur, called vaccine-related hypermetabolic lymphadenopathy, which is considered reactive lymphadenopathy. We report here a case of Kikuchi-Fujimoto disease, which occurred three months after vaccination with COVID-19 vaccine. The patient had cervical and axillary lymph node enlargement and a short-term fever that resolved spontaneously after the first and second vaccines. On the 90th day after the first vaccination, the patient developed a high fever and pathologically diagnosed necrotizing lymphadenitis in the axilla, which was diagnosed as Kikuchi-Fujimoto disease. Gallium scintigraphy showed localized swelling and strong uptake in the ipsilateral axilla. It implies the possibility of Kikuchi-Fujimoto Disease in axillary drainage lymph nodes in association with COVID-19 vaccine. Although only a few cases have been reported so far, this case is novel because of its later onset and diagnosis based on pathological and gallium scintigraphy imaging findings.

Keywords: COVID-19; COVID-19 vaccine; Kikuchi-Fujimoto disease; fever of unknown origin; lymphadenopathy; mRNA vaccine; necrotizing histiocytic lymphadenitis.

Publication types

  • Case Reports

MeSH terms

  • COVID-19 Vaccines* / adverse effects
  • COVID-19* / prevention & control
  • Gallium*
  • Histiocytic Necrotizing Lymphadenitis* / complications
  • Histiocytic Necrotizing Lymphadenitis* / diagnosis
  • Histiocytic Necrotizing Lymphadenitis* / pathology
  • Humans
  • Lymph Nodes
  • Lymphadenopathy* / diagnostic imaging
  • Lymphadenopathy* / etiology
  • Vaccination / adverse effects

Substances

  • COVID-19 Vaccines
  • Gallium

Grants and funding

The author(s) reported there is no funding associated with the work featured in this article.